<?xml version="1.0" encoding="UTF-8"?>
<xml>
 <records>
  <record>
   <ref-type name="Journal Article">17</ref-type>
   <contributors>
    <authors/>
   </contributors>
   <titles>
    <title></title>
   </titles>
   <dates>
    <year>2021</year>
    <pub-dates>
     <date>2021-05-28</date>
    </pub-dates>
   </dates>
   <doi>10.1016/j.bmcl.2021.128055</doi>
   <abstract>The antibacterial properties of close noscapine analogs have not been previously reported. We used our pDualrep2 double-reporter High Throughput Screening (HTS) platform to identify a series of noscapine derivatives with promising antibacterial activity. The platform is based on RPF (SOS-response/DNA damage) and Katushka2S (inhibition of translation) proteins and simultaneously provides information on antibacterial activity and the mechanism of action of small-molecule compounds against E. coli. The most potent compound exhibited an MIC of 13.5 µM (6.25 µg/ml) and a relatively low cytotoxicity against HEK293 cells (CC50 = 71 µM, selectivity index: ~5.5). Some compounds from this series induced average Katushka2S reporter signals, indicating inhibition of translation machinery in the bacteria; however, these compounds did not attenuate translation in vitro in a luciferase-based translation assay. The most effective compounds did not significantly arrest the mitotic cycle in HEK293 cells, in contrast to the parent compound in a flow cytometry assay. Several molecules showed activity against clinically relevant gram-negative and gram-positive bacterial strains. Compounds from the discovered series can be reasonably regarded as good templates for further development and evaluation.</abstract>
   <urls>
    <web-urls>
     <url>https://repo.bashgmu.ru/publication/1843</url>
    </web-urls>
    <pdf-urls>
     <url>https://repo.bashgmu.ru/files/2015</url>
    </pdf-urls>
   </urls>
  </record>
 </records>
</xml>
